HoneyNaps Concludes a Meaningful Participation at World Sleep 2025 -- Global Spotlight on AI Sleep Medicine Technology

• Six contracts signed — business expansion accelerates across Europe, Latin America, and the Middle East
• FDA-approved AI PSG Auto-scoring solution SOMNUM recognized for high clinical applicability
• Company pursues global partnerships and medical device certifications while building local distributor networks

BOSTON, Oct. 16, 2025 /PRNewswire/ -- AI-based sleep medical solution provider HoneyNaps USA announced on September 18 that it successfully concluded its participation in the 18th World Sleep Congress (World Sleep 2025) held from September 5 to 10 at the Suntec Convention & Exhibition Centre in Singapore. Through this Congress, HoneyNaps USA showcased its core technologies to global medical professionals and achieved tangible results in expanding global partnerships.

The World Sleep Congress is an international congress that gathers sleep medicine experts and companies from around the world. HoneyNaps USA drew significant attention by exhibiting two versions of its FDA-approved AI-based Polysomnography (PSG) automatic scoring solution: the installable SOMNUM Pro and the web-based SOMNUM Cloud.

SOMNUM Pro is a stand-alone software that can be installed on hospital computers. It automatically scores PSG data using AI to generate polysomnography reports and provides a scoring window that visually shows how the AI scored each event.

SOMNUM Cloud is a web-based version that requires no software installation. Users simply upload EDF files extracted from PSG equipment, and the AI automatically scores the data and provides downloadable Polysomnography report. In addition to providing raw data score results, SOMNUM Cloud operates on a secure server that meets both HIPAA regulations and ISO/IEC 27001 certification, earning high marks for medical data protection.

During the congress, medical professionals from more than 35 countries visited the HoneyNaps USA booth — including industrialized country markets like the UK, France, and Germany, as well as Latin American nations such as Brazil and Mexico, Asian countries like China, Japan, and Taiwan, and Middle Eastern regions including Saudi Arabia and the UAE. Although the exhibition was relatively modest in scale, the company reported a higher visitor turnout compared to the previous SLEEP 2025, and the Congress of the ESRS, reflecting the growing enthusiasm in the field.

Over 260 business inquiries were made during the congress, which led to six signed contracts. Additionally, active discussions were conducted for exclusive distributorship agreements in multiple countries, with follow-up negotiations underway regarding specific contract terms and supply models. More than 150 trial applications were also received from participants interested in experiencing AI Auto-scoring using SOMNUM Cloud. Based on these, HoneyNaps USA plans to establish country-specific customer support and product deployment strategies.

Taekyoung (Sean) Ha, PhD, President of HoneyNaps USA, stated, "We will begin by following up with the trial applicants we signed up at the exhibition, while simultaneously establishing local distributor systems and pursuing regulatory approval processes for medical devices in key target countries. As a leading company in the global commercialization of AI sleep medical technology, we aim to rapidly expand our presence in the international healthcare market through not only technological excellence but also practical service delivery and strong partnerships."

Based on the global demand and feedback collected at the exhibition, HoneyNaps USA plans to accelerate its overseas expansion efforts. The company will initially focus on engaging with trial customers while gradually advancing regulatory approval processes for medical devices across different countries. It also intends to establish official distributor networks — particularly in regions with strong market response such as Europe and the Middle East — and is considering expanding field applications through joint research and pilot projects with medical institutions.

For further information, please contact:
HoneyNaps USA, Inc.
Christine Kwon / Managing Director
Email: [email protected]
Address: #517, SPACES, 361 Newbury Street, Boston, MA, 02115
Website: www.honeynaps.com

SOURCE HoneyNaps